Form 4: Coherus BioSciences CFO Bryan J. McMichael Acquires 75,000 Stock Options
SEC Form 4 Filing
Bryan J. McMichael, CFO of Coherus BioSciences, acquired 75,000 stock options at an exercise price of $1.24 on August 7, 2024.
Summary
- On August 7, 2024, Bryan J. McMichael, the Chief Financial Officer of Coherus BioSciences, Inc. [CHRS], acquired 75,000 stock options.
- The exercise price for these options is $1.24.
- The options vest over a period of four years, with 1/4th vesting on August 1, 2025, and the remaining 1/48th vesting monthly thereafter, contingent upon continued service with the company.
- The expiration date for these options is August 7, 2034.
- Following the transaction, Mr. McMichael directly owns 75,000 derivative securities.
Sentiment
Score: 7
Explanation: The sentiment is neutral to positive. The granting of stock options is a standard practice and indicates confidence in the company's future. There are no immediate negative implications.
Positives
- The acquisition of stock options by the CFO signals confidence in the company's future performance.
Future Outlook
The vesting schedule suggests a long-term commitment from the CFO to the company's success.
Industry Context
Stock option grants are a common form of executive compensation in the biotechnology industry, aligning management's interests with those of shareholders.
Comparison to Industry Standards
- Executive compensation packages, including stock options, are common in the biotech industry to incentivize performance and align executive interests with shareholder value.
- Companies like Amgen, Gilead Sciences, and Biogen also utilize stock options as part of their executive compensation plans.
- The vesting schedule and exercise price are typical for stock option grants in similar companies.
Stakeholder Impact
- Shareholders may view the stock option grant as a positive sign, aligning management's interests with the company's long-term success.
- Employees may see this as a sign of stability and potential growth within the company.
Key Dates
| Date | Description |
|---|---|
| 08/01/2024 | Vesting start date for the stock options (1/4th of the total shares). |
| 08/07/2024 | Date of transaction: CFO acquired stock options. |
| 08/09/2024 | Date of Form 4 filing. |
| 08/07/2034 | Expiration date of the stock options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.